[HTML][HTML] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - Pulmonology, 2019 - Elsevier
Background Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
[PDF][PDF] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - scholar.archive.org
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2---
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
[PDF][PDF] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - core.ac.uk
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2---
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2-5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
[引用][C] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - Pulmonology, 2019 - cir.nii.ac.jp
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian
referral centre | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
referral centre | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF][PDF] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - academia.edu
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2---
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - …, 2018 - europepmc.org
Background Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2-5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - …, 2018 - usiena-air.unisi.it
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression …
[引用][C] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - PULMONOLOGY, 2019 - flore.unifi.it
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian
referral centre IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT …
referral centre IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT …
[PDF][PDF] Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi… - usiena-air.unisi.it
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2---
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …
5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease …